I am on the GSK Syneos contract. I don't think anyone is going to know the answer about if we stay or go until around December. Who knows, it could stay. I wouldn't take that chance, though, if I was looking for a new opportunity. It would be better to wait.
Just got a call from a recruiter about filling a Breo opening. On the GSK tanzeum contract, a friend of mine was hired and didn't make it to inhouse training before they killed the contract. Never know with GSK
I don't think that is just with GSK. I think that rule applies with any contract. This contracted started off as Advair and has been going on for almost 5 years. Long time for contract! But it could be winding down. It had a very good run if it does end, which is no fault of anyone who interviews. In my opinion, it's better to interview with brand new contracts just starting, instead of at the end when it's already had a long run.
It’s really hard to read on this one....I will just read what’s out there, as someone has stated above and it’s a great point, this contract has been going on for quite sometime. If they are still recruiting, what does that say about the GSK side? This situation seems a bit different from the past. You can check out the GSK board, I don’t think most know what the future holds for either.
It has been a great contract for those who got on earlier. I'd imagine it's one of their longer running contracts ever? As for taking a position now, it's 50/50 what they will do at the end of the year. If the contract holds, then I'd say it would be a good one to interview for. But not right now while everyone is waiting to get word on if it'll stay or go.
The Breo contract is done. Trelogy is actively selling against Breo. What kind of sense does that make?
I don't know about it being done, but it makes perfect sense. Remember when Advair launched, it was Advair for all. Now it will be Trelegy for all. GSK is unethical and really cares only for the bottom line. Breo is only being positioned for asthma not because of the GOLD guidelines for COPD but because of patents. Since when did GSK ever care about guidelines before? Advair generic and soon to be Symbicort. GSK is screaming from the rooftops that LABA/LAMA's makes the most sense to be used first because of guidelines. Complete BS. That class makes sense because of patient protection and no generic entries happening anytime soon. For over a decade the ICS/LABA's did a great job with COPD symptoms and exacerbations, now it is almost like they don't work. Comical. Ask yourself, why was the Trelegy exacerbation difference w/ Anoro more robust as compared to Breo? Because the LABA/LAMA's aren't as effective at reducing exacerbations. By using the ICS as the third leg to the stool, GSK can protect their franchise while saying they are aligning to GOLD.
That doesn't mean the contract will end. They could get Trelegy next year either selling it alongside with GSK reps, or selling it solo on the contract.
